androstane-3,17-diol has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbiati, F; Audano, M; Azcoitia, I; Brioschi, E; Caruso, D; Cermenati, G; Crestani, M; De Fabiani, E; Garcia-Segura, LM; Giatti, S; Melcangi, RC; Mitro, N | 1 |
| Bianchi, R; Camozzi, F; Caruso, D; Cavaletti, G; Crippa, D; Garcia-Segura, LM; Giatti, S; Lauria, G; Melcangi, RC; Roglio, I; Scurati, S | 1 |
2 other study(ies) available for androstane-3,17-diol and Alloxan Diabetes
| Article | Year |
|---|---|
Neuroactive steroid treatment modulates myelin lipid profile in diabetic peripheral neuropathy.
Topics: 20-alpha-Dihydroprogesterone; Anabolic Agents; Androstane-3,17-diol; Animals; Biomarkers; Chromatography, Liquid; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Lipids; Male; Myelin Sheath; Peripheral Nervous System Diseases; Progestins; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sciatic Nerve; Tandem Mass Spectrometry | 2014 |
Testosterone derivatives are neuroprotective agents in experimental diabetic neuropathy.
Topics: Anabolic Agents; Androstane-3,17-diol; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dihydrotestosterone; Male; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Testosterone | 2007 |